sur NOVACYT (EPA:ALNOV)
Novacyt SA recorded 18% growth in the first half of 2026
Novacyt SA announces an 18% increase in its unaudited revenue for the first half of 2026, reaching approximately £11.6 million. This increase includes sustained organic growth, notably excluding the contribution of Southern Cross Diagnostics (SCD).
Instrumentation sales jumped 30%, thanks to the LightBench Discover platform. The Clinical segment also saw an increase of over 20%, driven by NIPT technology and contributions from SCD. The Americas and Asia-Pacific regions saw revenue growth of over 30% and 22%, respectively.
The cash position stands at £8.9 million, a decrease partly due to the acquisition of SCD for £5.5 million. In addition, Novacyt raised approximately €785,000 through a capital increase.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NOVACYT